Streetbeat News

KNBIF

Kane Biotech Inc.

Industry

Research and Development in Biotechnology

Open

0.10

Mkt cap

10M

Volume

High

0.10

P/E Ratio

-3.83

52-wk high

0.12

Low

0.08

Div yield

N/A

52-wk low

0.04

Kane Biotech Inc. has received Health Canada approval for its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device, potentially boosting its market presence and sales.

Portfolio Pulse from

November 14, 2024 | 6:30 pm

Kane Biotech has provided an investor update following the announcement of its acquisition of FB Dermatology. The company's leadership, including President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga, discussed the strategic opportunity this acquisition presents.

Portfolio Pulse from

November 14, 2024 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.